U.S., March 1 -- ClinicalTrials.gov registry received information related to the study (NCT06851403) titled 'The Effectiveness and Safety of Dupilumab in Children with Asthma in China: a Real-world Study' on Oct. 03, 2024.
Brief Summary: Observe the changes of type II inflammation markers, lung function, and symptom scores in asthmatic patients aged 6 to 14 during the use of dupilumab to analyze its efficacy.
Study Start Date: Jan. 30, 2022
Study Type: OBSERVATIONAL
Condition:
Asthma in Children
Intervention:
DRUG: Dupilumab
initial injection of 600 mg, followed by maintenance injections of 300 mg every four weeks
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Guangzhou Institute of Respiratory Disease
Information provided ...